These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 4849639

  • 1. [Results of therapy with Lyogen-Depot in schizophrenic diseases].
    Friemert K, Beier R, Vehreschild T.
    Psychiatr Neurol Med Psychol (Leipz); 1974 Jun; 26(6):374-7. PubMed ID: 4849639
    [No Abstract] [Full Text] [Related]

  • 2. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study.
    Levine J, Schooler NR, Severe J, Escobar J, Gelenberg A, Mandel M, Sovner R, Steinbook R.
    Adv Biochem Psychopharmacol; 1980 Jun; 24():483-93. PubMed ID: 6996445
    [No Abstract] [Full Text] [Related]

  • 3. [Experience with the depot neuroleptic LyogenR-depot].
    Bach O, Petermann H, Geppert V.
    Psychiatr Neurol Med Psychol (Leipz); 1978 Sep; 30(9):563-6. PubMed ID: 733993
    [Abstract] [Full Text] [Related]

  • 4. [Prolonged treatment of schizophrenic psychoses with depot-fluphenazine ("lyogen decanoate")].
    Bohacek N, Mihovilović M.
    Neuropsihijatrija; 1968 Sep; 16(3):69-73. PubMed ID: 5195835
    [No Abstract] [Full Text] [Related]

  • 5. [Experience with depot neuroleptics].
    Arató M, Erdós A.
    Orv Hetil; 1979 Apr 29; 120(17):1015-21. PubMed ID: 372888
    [No Abstract] [Full Text] [Related]

  • 6. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.
    Dencker SJ.
    J Clin Psychiatry; 1984 May 29; 45(5 Pt 2):22-7. PubMed ID: 6143744
    [Abstract] [Full Text] [Related]

  • 7. Depot fluphenazine: risk/benefit ratio.
    Glazer WM.
    J Clin Psychiatry; 1984 May 29; 45(5 Pt 2):28-35. PubMed ID: 6370986
    [Abstract] [Full Text] [Related]

  • 8. Dosage and side effect comparisons betweel oral and depot fluphenazine.
    Schooler NR, Levine J.
    Psychopharmacol Bull; 1977 Jul 29; 13(3):29-31. PubMed ID: 329328
    [No Abstract] [Full Text] [Related]

  • 9. [Depot fluphenazine as a means of stabilizing remission in cases of schizophrenia].
    Vovin RIa, Vovina EN.
    Psychiatr Neurol Med Psychol Beih; 1975 Jul 29; 20-21():183-7. PubMed ID: 829620
    [Abstract] [Full Text] [Related]

  • 10. Long-acting phenothiazines for treatment of schizophrenia.
    Med Lett Drugs Ther; 1976 Jan 16; 18(2):6-7. PubMed ID: 1107791
    [No Abstract] [Full Text] [Related]

  • 11. [Long-term therapy with depot-fluphenazine Dapotum in schizophrenia].
    Moldenhauer B.
    Med Welt; 1966 Jul 02; 27():1477-81. PubMed ID: 5985539
    [No Abstract] [Full Text] [Related]

  • 12. [Evaluation of fluphenazine use since establishment of a psychiatric section].
    Roger BM.
    Ann Med Psychol (Paris); 1972 Apr 02; 1(4):550-5. PubMed ID: 4342755
    [No Abstract] [Full Text] [Related]

  • 13. Depot fluphenazine in the prevention of relapse in schizophrenia: evaluation of a treatment regimen [proceedings].
    Schooler NR, Levine J, Severe JB.
    Psychopharmacol Bull; 1979 Apr 02; 15(2):44-7. PubMed ID: 373006
    [No Abstract] [Full Text] [Related]

  • 14. Prolixin enanthate and thorazine-stelazine regimens in the treatment of schizophrenic patients. An experimental evaluation.
    DeWolfe AS, Barrell RP, London L, Spaner FE.
    Psychosomatics; 1971 Apr 02; 12(3):186-90. PubMed ID: 4950862
    [No Abstract] [Full Text] [Related]

  • 15. [Clinical and ambulatory experiences with fluphenazine decanoate lyogen depot in prolonged therapy of psychiatric disorders].
    Moldenhauer B.
    Med Welt; 1970 Jun 20; 25():1150-4. PubMed ID: 5512636
    [No Abstract] [Full Text] [Related]

  • 16. Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.
    Wiles DH, Gelder MG.
    Adv Biochem Psychopharmacol; 1980 Jun 20; 24():599-602. PubMed ID: 7405678
    [No Abstract] [Full Text] [Related]

  • 17. [Characteristics of the therapeutic action fluphenzaine decanoate (moditen-depot) in schizophrenia].
    Tsutsul'kovskaia MIa, Minsker EI, Panteleeva GP, Mazurskii MB, Pekunova LG.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973 Jun 20; 73(5):753-8. PubMed ID: 4718619
    [No Abstract] [Full Text] [Related]

  • 18. Fluphenazine decanoate and fluphenazine enanthate in the out-patient management of chronic schizophrenia.
    MacCrimmon DJ, Saxena B, Foley P, Grof P.
    Neuropsychobiology; 1978 Jun 20; 4(6):360-5. PubMed ID: 692838
    [Abstract] [Full Text] [Related]

  • 19. [Effect of moditen-depot therapy on the duration and quality of remissions in schizophrenia patients].
    Vovin RIa, Gurovich IIa, Eryshev OF, Zaĭtsev SG, Magalif AIu.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1977 Jun 20; 77(5):743-9. PubMed ID: 899478
    [Abstract] [Full Text] [Related]

  • 20. Speed and rate of remission in acute schizophrenia: a comparison of intramuscularly administered fluphenazine HC1 with thiothixene and haloperidol.
    Levenson AJ, Burnett GB, Nottingham JD, Sermas CE, Thornby JI.
    Curr Ther Res Clin Exp; 1976 Nov 20; 20(5):695-700. PubMed ID: 825356
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.